{
  "source": "PA-Notification-Forteo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1033-16\nProgram Prior Authorization/Notification\nMedication Forteo® (teriparatide)*, Teriparatide Injection (teriparatide)\nP&T Approval Date 8/2008, 8/2009, 7/2010, 7/2011, 8/2012, 11/2013, 10/2014, 10/2015,\n9/2016, 7/2017, 11/2017, 11/2018, 11/2019, 9/2020, 1/2021, 1/2022,\n1/2023, 2/2023, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nForteo (teriparatide)* and Teriparatide Injection (teriparatide) are recombinant human parathyroid\nhormone with three FDA approved indications1-2:\n• Treatment of postmenopausal patients with osteoporosis at high risk of fracture\nForteo and Teriparatide Injection are indicated for the treatment of postmenopausal patients with\nosteoporosis who are at high risk for fracture, defined as a history of osteoporotic fracture,\nmultiple risk factors for fracture, or patients who have failed or are intolerant to other available\nosteoporosis therapy.\n• Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for\nfracture\nForteo and Teriparatide Injection are indicated to increase bone mass in patients with primary or\nhypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture,\nmultiple risk factors for fracture, or patients who have failed or are intolerant to other available\nosteoporosis therapy.\n• Treatment of patients with glucocorticoid-induced osteoporosis at high risk for fracture\nForteo and Teriparatide Injection are indicated for the treatment of patients with osteoporosis\nassociated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or\ngreater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture,\nmultiple risk factors for fracture, or patients who have failed or are intolerant to other available\nosteoporosis therapy.\nForteo* and Teriparatide Injection for more than 2 years during a patient’s lifetime should only be\nconsidered if ",
    "r patients who have failed or are intolerant to other available\nosteoporosis therapy.\nForteo* and Teriparatide Injection for more than 2 years during a patient’s lifetime should only be\nconsidered if a patient remains at or has returned to having a high risk for fracture.1-2\nThe American Association of Clinical Endocrinologists/American College of Endocrinology\nAACE/ACE) recommend the use of teriparatide be considered for patients unable to use oral therapy\nand as initial therapy for patients at very high fracture risk defined as the following: patients with a\nrecent fracture (e.g., within the past 12 months), fractures while on approved osteoporosis therapy,\nmultiple fractures, fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids),\nvery low T-score (e.g., less than −3.0), high risk for falls or history of injurious falls, and very high\nfracture probability by FRAX® (fracture risk assessment tool) (e.g., major osteoporosis fracture\n>30%, hip fracture >4.5%) or other validated fracture risk algorithm to be at very high fracture risk.3\nAdditionally, the AACE/ACE and Endocrine Society both recommend to limit treatment with\nteriparatide to 2 years.3-4\nCoverage will be provided for members who meet the following criteria.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Coverage Criteriaa:\nA. Osteoporosis\n1. Forteo* and Teriparatide Injection will be approved based on all of the following\ncriteria:\na. One of the following:\n(1) Both of the following:\n(a) Patient is female\n-AND-\n(b) Diagnosis of postmenopausal osteoporosis\n-OR-\n(2) Both of the following:\n(a) Patient is male\n-AND-\n(b) Diagnosis of osteoporosis\n-AND-\nb. One of the following:\n(1) Patient is at high risk of fracture [e.g., recent fracture (e.g., within the past 12\nmonths), fractures while on approved osteoporosis therapy, multiple fractures,\nfractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids),\nvery low T-score (e.g., less than −3.0), high risk for falls or his",
    "approved osteoporosis therapy, multiple fractures,\nfractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids),\nvery low T-score (e.g., less than −3.0), high risk for falls or history of injurious\nfalls, and very high fracture probability by FRAX® (fracture risk assessment\ntool) (e.g., major osteoporosis fracture >30%, hip fracture >4.5%)]\n-OR-\n(2) Patient has a history of failure, intolerance or contraindication to other available\nosteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate)\n-AND-\nc. One of the following:\n(1) Treatment duration has not exceeded a total of 24 months of cumulative use of\n© 2024 UnitedHealthcare Services, Inc.\n2\nparathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-OR-\n(2) Both of the following:\n(a) Patient is currently or has previously been treated with parathyroid hormone\nanalogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-AND-\n(b) The prescriber attests that the patient remains at or has returned to having a\nhigh risk for fracture\nAuthorization will be issued for 24 months.\n2. Reauthorization\na. Forteo and Teriparatide Injection will be approved based on both of the\nfollowing criteria:\n(1) The prescriber attests that the patient remains at or has returned to having a high\nrisk for fracture despite 24 months of cumulative use of parathyroid hormone\nanalogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-AND-\n(2) The prescriber attests that the risk versus benefit of use greater than 24 months\nof cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection,\nForteo, Tymlos) has been reviewed with the patient\nAuthorization will be issued for 12 months.\nB. Osteoporosis Associated with Sustained Systemic Glucocorticoid Therapy\n1. Forteo and Teriparatide Injection will be approved based on all of the following\ncriteria:\na. Diagnosis of glucocorticoid-induced osteoporosis\n-AND-\nb. History of prednisone or its equivalent at a dose ≥ 5 mg/day\n-AND-\nc. One of the f",
    "will be approved based on all of the following\ncriteria:\na. Diagnosis of glucocorticoid-induced osteoporosis\n-AND-\nb. History of prednisone or its equivalent at a dose ≥ 5 mg/day\n-AND-\nc. One of the following:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Patient is at high risk of fracture [e.g., recent fracture (e.g., within the past 12\nmonths), fractures while on approved osteoporosis therapy, multiple fractures,\nfractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids),\nvery low T-score (e.g., less than −3.0), high risk for falls or history of injurious\nfalls, and very high fracture probability by FRAX® (fracture risk assessment\ntool) (e.g., major osteoporosis fracture >30%, hip fracture >4.5%)]\n-OR-\n(2) Patient has a history of failure, intolerance or contraindication to other available\nosteoporosis therapy (e.g., alendronate, denosumab, risedronate, zoledronate)\n-AND-\nd. One of the following:\n(1) Treatment duration has not exceeded a total of 24 months of cumulative use of\nparathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-OR-\n(2) Both of the following:\n(a) Patient is currently or has previously been treated with parathyroid\nhormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-AND-\n(b) The prescriber attests that the patient remains at or has returned to having a\nhigh risk for fracture\nAuthorization will be issued for 24 months.\n2. Reauthorization\na. Forteo and Teriparatide Injection will be approved based on both of the\nfollowing criteria:\n(1) The prescriber attests that the patient remains at or has returned to having a high\nrisk for fracture despite 24 months of cumulative use of parathyroid hormone\nanalogs (e.g., Teriparatide Injection, Forteo, Tymlos)\n-AND-\n(2) The prescriber attests that the risk versus benefit of use greater than 24 months\nof cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection,\nForteo, Tymlos) has been reviewed with the patient\nAuthorization will be issued",
    "us benefit of use greater than 24 months\nof cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection,\nForteo, Tymlos) has been reviewed with the patient\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Forteo is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to plan\nspecifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Exclusion: Forteo is excluded from coverage for the majority of our benefits\n• Medical Necessity, Supply Limits and/or Step Therapy may be in place.\n4. References:\n1. Forteo [package insert]. Indianapolis, IN: Eli Lilly, Inc.; July 2024.\n2. Teriparatide Injection [package insert]. Morristown, NJ: Alvogen, Inc.; November 2023.\n3. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical\nPractice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020\nUpdate. Endocr Pract. 2020;26(Supp1): 1-46.\n4. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological\nManagement of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline\nUpdate. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa048.\nProgram Prior Authorization/Notification - Forteo (teriparatide)\nChange Control\n11/2013 Annual review. Added diagnosis criteria for osteoporosis and\nglucocorticoid-induced osteoporosis. Added criteria to allow coverage\nwhen both of the following are met: ‘history of vertebral compression",
    "Annual review. Added diagnosis criteria for osteoporosis and\nglucocorticoid-induced osteoporosis. Added criteria to allow coverage\nwhen both of the following are met: ‘history of vertebral compression\nfracture, fracture of the hip or fracture of the distal radius resulting from\nminimal trauma’ and ‘history of failure, contraindication, or intolerance\nto one conventional osteoporosis therapy.’ Added ‘history of failure,\ncontraindication, or intolerance to one conventional osteoporosis\ntherapy’ as one of the criteria required in addition to ‘BMD T-score\nbetween -1.0 and -2.0.’\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n10/2014 Annual review with no change to clinical criteria.\n10/2015 Annual review with no change to clinical criteria.\n9/2016 Annual review. No change to clinical criteria. Updated references.\n7/2017 Annual Review. Updated language to remove gender references,\nupdated references, updated diagnosis criteria for osteoporosis to\ninclude history of fragility fractures, and FRAX assessment tool, added\nfractures of proximal humerus and pelvis as examples of fragility\nfractures. Updated approval to include cumulative use of parathyroid\nhormone analogs.\n11/2017 Added requirement for BMD T-score submission and previous\nmedication trial documentation. Added physician attestation criterion.\n© 2024 UnitedHealthcare Services, Inc.\n5\n11/2018 Annual review with no change to clinical criteria. Updated references.\n11/2019 Annual review with no change to clinical criteria. Updated references.\n9/2020 Added Teriparatide Injection to the program. Updated criteria to reflect\nchange in preferred product and Forteo exclusion for 1/1/2021.\nRenamed section headers to match step therapy program. Updated\nbackground and references.\n1/2021 Updated criteria based on changes to prescribing information on use\nbeyond 2 years. References updated.\n1/2022 Annual review with no change to clinical criteria. Updated background\nand references.\n1/2023 ",
    "ted criteria based on changes to prescribing information on use\nbeyond 2 years. References updated.\n1/2022 Annual review with no change to clinical criteria. Updated background\nand references.\n1/2023 Annual review with no change to clinical criteria. Updated exclusion\nstatement, added state mandate footnote and updated references.\n2/2023 Updated coverage criteria confirming osteoporosis diagnosis and high\nfracture risk to align with current treatment guidelines. Updated\nbackground and references.\n10/2023 Annual review. Updated background and coverage criteria to align with\nthe label and treatment guidelines. Removed “routine audit” language\nfrom criteria. Updated references.\n10/2024 Annual review with no change to coverage criteria. Updated\nbackground and references.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}